Emerging markets present unique opportunities and challenges for pharmacovigilance professionals.
Introduction
The global pharmaceutical landscape is changing rapidly, with emerging markets becoming increasingly important for clinical development, product launches, and patient access to medicines.
Countries across Asia, Latin America, the Middle East, and Africa offer significant opportunities for pharmaceutical organizations. However, operating in these markets can also introduce unique pharmacovigilance challenges.
Differences in healthcare infrastructure, regulatory maturity, reporting practices, medical terminology, patient populations, technology adoption, and access to safety data can make pharmacovigilance operations more complex.
For organizations expanding into emerging markets, building a strong and adaptable safety system is essential to ensure that potential risks are identified, assessed, documented, and communicated appropriately.
In this article, we explore the key opportunities and challenges associated with pharmacovigilance in emerging markets and discuss strategies organizations can use to strengthen their safety operations.
1. Growing Importance of Emerging Markets
Emerging markets are becoming increasingly important in the global life sciences industry.
Growing healthcare investment, expanding patient populations, improved access to medicines, and increasing clinical research activity are contributing to the growth of pharmaceutical markets across these regions.
As more medicines become available to patients, the need for effective pharmacovigilance systems also increases.
Organizations operating in multiple emerging markets need to understand local safety requirements while maintaining consistent global pharmacovigilance standards.
Tip:
Develop a market-specific pharmacovigilance strategy that considers local regulations, healthcare infrastructure, reporting practices, and patient needs.
2. Differences in Regulatory Requirements
One of the major challenges in emerging markets is the variation in regulatory requirements.
Each country may have its own expectations regarding:
- Adverse event reporting
- Safety reporting timelines
- Local safety officers
- Pharmacovigilance systems
- Risk management activities
- Periodic safety reports
- Local literature monitoring
- Regulatory submissions
- Safety documentation
Although many regulatory authorities align their requirements with international standards, local differences can still be significant.
Tip:
Maintain a centralized regulatory intelligence process to monitor changes in pharmacovigilance requirements across every market where products are marketed.
3. Limited Adverse Event Reporting
Under-reporting of adverse events can be a significant challenge in emerging markets.
Patients and healthcare professionals may not always report suspected adverse events because of limited awareness, lack of reporting channels, time constraints, or uncertainty about what should be reported.
Limited reporting can make it more difficult for organizations to identify potential safety signals.
Organizations should therefore work toward making safety reporting simple, accessible, and understandable.
Tip:
Improve awareness among healthcare professionals and patients by providing clear reporting channels, educational resources, and easy-to-use reporting mechanisms.
4. Healthcare Infrastructure Challenges
Healthcare infrastructure can vary significantly between regions and even within individual countries.
Urban areas may have access to advanced hospitals, digital healthcare systems, and specialist medical services, while rural or remote areas may have fewer resources.
These differences can affect the availability and quality of safety information.
Limited access to electronic health records, laboratory data, specialist assessments, and digital reporting systems can create additional challenges for pharmacovigilance teams.
Tip:
Design flexible safety processes that can work effectively across both highly digital and resource-limited healthcare environments.
5. Data Quality & Completeness
High-quality safety data is essential for effective pharmacovigilance.
In emerging markets, organizations may encounter incomplete reports, missing patient information, unclear medical descriptions, inconsistent documentation, or limited follow-up information.
Poor data quality can make it difficult to evaluate cases accurately and may affect signal detection and benefit-risk assessments.
Strong case validation and follow-up processes can help improve the quality and completeness of safety information.
Tip:
Establish clear case intake and follow-up procedures to obtain missing information and improve the overall quality of safety reports.
6. Language & Cultural Differences
Language diversity can create additional complexity for global pharmacovigilance operations.
Safety reports may be submitted in local languages and may include region-specific medical terminology, abbreviations, or descriptions of symptoms.
Cultural differences can also influence how patients describe their experiences with medicines and how healthcare professionals communicate safety information.
Organizations need appropriate processes for translation, medical review, terminology standardization, and data interpretation.
Tip:
Use qualified language and medical resources to ensure that safety information is translated accurately without losing important clinical meaning.
7. Local Pharmacovigilance Expertise
Some emerging markets may have a smaller pool of experienced pharmacovigilance professionals compared with more established pharmaceutical markets.
Organizations entering these markets may need to invest in training, knowledge development, and local expertise.
Local professionals can provide valuable insight into healthcare practices, regulatory expectations, reporting behaviors, and cultural factors that may not be fully understood from a global perspective.
Tip:
Build strong local capabilities while maintaining global pharmacovigilance standards, procedures, and quality oversight.
8. Technology Adoption & Digital Transformation
Digital transformation is creating new opportunities for pharmacovigilance in emerging markets.
Mobile technologies, cloud platforms, electronic reporting systems, artificial intelligence, and advanced analytics can help organizations improve safety data collection and processing.
Digital solutions can be particularly valuable where traditional healthcare infrastructure is limited.
For example, mobile reporting channels can make it easier for healthcare professionals and patients to submit safety information from locations where access to traditional reporting systems may be limited.
Tip:
Choose technology solutions that are scalable, secure, user-friendly, and appropriate for the local healthcare and digital infrastructure.
9. Real-World Data Opportunities
Emerging markets can provide valuable real-world safety information because of their diverse patient populations and healthcare environments.
Real-world data can come from sources such as:
- Electronic health records
- Patient registries
- Healthcare databases
- Claims data
- Digital health platforms
- Medical literature
- Patient support programs
When appropriately collected and evaluated, these sources can provide additional insight into medicine use and patient safety.
Tip:
Establish clear data governance and quality standards before using real-world data for pharmacovigilance activities.
10. Third-Party & Partner Management
Pharmaceutical organizations often work with local distributors, license partners, contract research organizations, medical information providers, and other third parties in emerging markets.
These partners may receive safety information before it reaches the central pharmacovigilance organization.
This creates the need for strong agreements, clearly defined responsibilities, training, escalation procedures, and ongoing oversight.
Weak third-party processes can result in delayed reporting, incomplete information, or inconsistent safety data management.
Tip:
Establish clear pharmacovigilance agreements with partners and regularly assess their performance through training, monitoring, audits, and quality reviews.
11. Literature Monitoring
Medical literature can be an important source of safety information in emerging markets.
However, local publications may not always be available through the same databases used for global literature monitoring.
Organizations may therefore need additional strategies to identify relevant local publications and safety information.
Local-language literature can also require specialized review and translation capabilities.
Tip:
Include appropriate local and regional sources in literature monitoring strategies and ensure that qualified reviewers can evaluate relevant publications.
12. Building a Risk-Based Pharmacovigilance Strategy
A one-size-fits-all approach may not be effective across emerging markets.
Organizations should evaluate each market based on factors such as:
- Patient population
- Product risk profile
- Regulatory requirements
- Reporting infrastructure
- Healthcare access
- Local expertise
- Data availability
- Partner network
- Digital maturity
This allows organizations to focus resources on the areas where they can have the greatest impact.
Tip:
Use risk-based assessments to determine the appropriate level of monitoring, oversight, training, and quality controls for each market.
13. Strengthening Training & Awareness
Education is one of the most effective ways to strengthen pharmacovigilance in emerging markets.
Healthcare professionals, local partners, employees, and other stakeholders should understand:
- What constitutes a safety report
- How to recognize potential adverse events
- Where to report safety information
- Reporting timelines
- Follow-up requirements
- Documentation expectations
- The importance of patient safety
Regular training can help improve reporting quality and create greater awareness of pharmacovigilance responsibilities.
Tip:
Use practical, locally relevant training materials and provide refresher training whenever requirements or processes change.
14. Ensuring Global Consistency With Local Flexibility
Global pharmaceutical organizations must balance two important priorities: consistency and flexibility.
Global pharmacovigilance standards help maintain consistent quality, governance, and oversight.
At the same time, local processes may need to be adapted to accommodate country-specific regulatory requirements, healthcare systems, languages, and reporting practices.
The most effective approach is often to establish a strong global framework supported by appropriately designed local procedures.
Tip:
Standardize core pharmacovigilance principles globally while allowing controlled flexibility for legitimate local requirements.
15. Preparing for Regulatory Inspections
As pharmacovigilance systems mature across emerging markets, organizations should be prepared for regulatory inspections.
Inspection readiness requires more than maintaining documentation. Organizations should be able to demonstrate that safety processes are implemented effectively and that responsibilities are understood across internal teams and external partners.
Important areas may include:
- Safety case processing
- Reporting timelines
- Signal management
- Risk management
- Training records
- Vendor oversight
- Safety agreements
- Quality management
- Data integrity
- CAPA effectiveness
Tip:
Conduct periodic internal assessments and mock inspections to identify weaknesses before a regulatory inspection occurs.
16. The Future of Pharmacovigilance in Emerging Markets
The future of pharmacovigilance in emerging markets will be increasingly digital, connected, and data-driven.
As healthcare infrastructure improves and regulatory frameworks continue to evolve, organizations will have greater opportunities to use technology for safety data collection, case processing, signal detection, and risk management.
Artificial intelligence, mobile reporting, cloud technologies, real-world data, and advanced analytics may significantly improve the ability to identify and evaluate safety concerns.
However, technology must be supported by strong governance, appropriate regulatory knowledge, trained professionals, and reliable data.
Tip:
Invest in scalable technologies and local capabilities that can evolve as the market’s healthcare and regulatory environment develops.
Conclusion
Emerging markets offer significant opportunities for pharmaceutical organizations, but successful pharmacovigilance requires an understanding of the unique challenges associated with each region.
Differences in regulatory requirements, healthcare infrastructure, reporting behavior, language, data quality, technology adoption, and local expertise can create operational complexity.
Organizations that combine strong global pharmacovigilance frameworks with local knowledge and flexible processes can build more effective safety systems.
By investing in training, technology, data quality, partner oversight, regulatory intelligence, and risk-based monitoring, organizations can strengthen pharmacovigilance capabilities while expanding access to medicines.
Ultimately, effective pharmacovigilance in emerging markets is about more than meeting regulatory requirements. It is about creating reliable systems that identify safety risks early, support informed benefit-risk decisions, and protect patients wherever medicines are used.
Strong local capabilities, supported by global pharmacovigilance standards, can create a safer and more sustainable path for growth in emerging markets.
